University of Maryland, Baltimore

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, University of Maryland, Baltimore sits in the top decile of US sponsors by registered trial count (#62 of 15,742 sponsors by registered trial count).

560 total trials 103 currently recruiting 332 completed early-phase tilt top decile by trial count

University of Maryland, Baltimore: 560 sponsored US clinical trials, 103 recruiting.

University of Maryland, Baltimore sponsors 560 registered US clinical trials on ClinicalTrials.gov, 103 of them currently recruiting, and 332 completed. 77 of these trials are in Phase 3-4 (later-stage) and 161 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Schizophrenia, with 14 trials.

Top-decile sponsor footprint

University of Maryland, Baltimore ranks in the top decile of sponsors by registered trial count (#62 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 42/100

332 of 410 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (81.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

560 total, page 10 of 12

TERMINATED Phase 2

Safety and Efficacy Challenge Study of CVD 1208S, a Live, Attenuated Oral Vaccine to Prevent Shigella: Phase IIb

NCT00866242

TERMINATED Phase 2

Safety and Efficacy Study of CVD 1208S, a Live, Attenuated Oral Vaccine to Prevent Shigella Infection: Phase IIa

NCT00866476

COMPLETED

Screening Protocol for Research Participants

NCT01010620

COMPLETED NA

Maximal Bruce Protocol With the Use of Regadenoson For Myocardial Perfusion Stress Testing

NCT01026012

TERMINATED Phase 4

Examining Genetic Influence on Response to Beta-Blocker Medications in People With Type 2 Diabetes

NCT00925119

COMPLETED

Dynamic Magnetic Resonance Imaging (MRI) for Lung Tumor Motion and Lung Function (GCC 0943)

NCT01016938

COMPLETED Phase 4

Salt Loading and Thiazide Intervention Study

NCT00896389

COMPLETED Phase 2

Effects of Oxytocin Nasal Spray on Social Affiliation

NCT00663039

COMPLETED NA

Preoperative Accelerated Partial Breast Irradiation (APBI) for Women With Stage I and Select IIA Breast Cancer

NCT01014715

COMPLETED NA

Nutrigenomics of Zinc Supplementation in Insulin Secretion and Diabetes

NCT00981448

COMPLETED NA

Challenge! Adolescent Obesity Prevention

NCT03103269

COMPLETED NA

An Integrated Approach to Smoking Cessation in Severe Mental Illness (SMI)

NCT00690131

COMPLETED Early Phase 1

Metabolic Causes of Thrombosis in Type 2 Diabetes Mellitus

NCT00829699

COMPLETED Phase 1

Class 3 Biowaivers

NCT01010698

COMPLETED NA

Duloxetine for Treatment of Painful Temporomandibular Joint Disorder

NCT00981149

COMPLETED Early Phase 1

Mechanisms of Hypoglycemia Associated Autonomic Dysfunction, Q4-Atomoxetine

NCT00780650

TERMINATED Phase 4

Tacrolimus to Sirolimus Conversion for Delayed Graft Function

NCT00931255

COMPLETED NA

Integrative Meditation (IM) for Cocaine Addiction

NCT01211418

COMPLETED NA

Pharmacogenomics of Thiazolidinediones

NCT01135394

COMPLETED Phase 4

Simvastatin With or Without Ezetimibe and Atherothrombotic Biomarker Assessment

NCT00819403

COMPLETED

Investigating the Improvement in 4D CT Images Using AV Biofeedback

NCT00780611

COMPLETED Phase 2

0822GCC: Phase 2 Study of Efficacy and Safety of Apricoxib/Placebo With Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer

NCT00771953

COMPLETED NA

Effects of Smoking Cues on Tobacco Craving Responses and the Reinforcing Efficacy of Cigarettes in Smokers With and Without Schizophrenia

NCT00770237

TERMINATED Phase 2

The Use of Oral Budesonide and Rectal Hydrocortisone for the Treatment of Active Ulcerative Colitis

NCT00805285

COMPLETED NA

GlideScope Versus Direct Laryngoscope for Emergency Intubation

NCT01235065

TERMINATED Phase 2

0794GCC: Pentamidine in Treating Patients With Relapsed or Refractory Melanoma

NCT00729807

TERMINATED Phase 4

Prevention of Anthracycline or Trastuzumab Induced Cardiomyopathy by Metoprolol

NCT00806390

COMPLETED NA

Gluten Free Diet in People With Schizophrenia: A Pilot Study

NCT01558557

COMPLETED NA

Mobile Diabetes Management

NCT01107015

COMPLETED Phase 4

Biomarker Study of Acamprosate in Schizophrenia

NCT00688324

TERMINATED NA

Side Effect Study of Antipsychotic Medicines to Treat Childhood Bipolar Disorder

NCT00746252

COMPLETED

Myocardial Glucose Uptake (MGU) in Patients With Chronic Kidney Disease

NCT00883415

COMPLETED

Bipolar and Schizophrenia Consortium for Parsing Intermediate Phenotypes

NCT00666432

COMPLETED NA

Acupuncture in Reducing Muscle and Bone Symptoms in Women Receiving Letrozole, Exemestane, or Anastrozole for Stage 0, Stage I, Stage II, or Stage III Breast Cancer

NCT00641303

COMPLETED Phase 3

The Home Telemanagement (UC HAT) Trial for Patients With Ulcerative Colitis

NCT00620126

COMPLETED Phase 4

Water Immersion in Right-Sided Heart Failure: A Pilot Study

NCT00654264

COMPLETED

Knowledge and Perception of Smoking Risks/Consequences

NCT00686101

TERMINATED Phase 2

The Effects of Rimonabant, on Weight and Metabolic Risk Factors

NCT00547118

COMPLETED NA

A Self-Management Program for Adults With Both Schizophrenia and a Co-occurring Medical Condition

NCT00525304

COMPLETED NA

Community-Based Care Management For Teen/Young Adult Mothers and Fathers

NCT00537108

COMPLETED Early Phase 1

Mechanisms of Hypoglycemia Associated Autonomic Dysfunction Question 2

NCT00574639

COMPLETED NA

Mindfulness Intervention For Child Abuse Survivors (MICAS)

NCT00867802

COMPLETED Phase 4

Varenicline Adjunctive Treatment in Schizophrenia

NCT00492349

COMPLETED Early Phase 1

Metabolic Causes of Thrombosis in Type 2 Diabetes - Question 4

NCT00574340

COMPLETED Phase 2

Dose Escalation Study Of Chinese Herbs In Osteoarthritis Of The Knee

NCT00755326

TERMINATED Early Phase 1

Mechanisms of Ramipril Reduction in the Onset of Type 2 Diabetes

NCT00574834

COMPLETED NA

Suspected Deficient Activation of Vitamin D in Patients With Secondary Hyperparathyroidism

NCT00754442

TERMINATED Phase 1

Safety of VSL#3 in Adult Asthmatics

NCT00852124

COMPLETED Phase 4

Rasagiline in the Treatment of Persistent Negative Symptoms of Schizophrenia

NCT00492336

COMPLETED NA

Evaluation of Renal Drug Transport in Healthy Volunteers

NCT00690014

← Previous Page 10 of 12 Next →

Phase Distribution

PhaseTrial count
Phase 1 82
Phase 2 79
Phase 3 10
Phase 4 67

What is open in the University of Maryland, Baltimore pipeline

103 recruiting of 560 indexed (18% open); 332 completed (59%).

Phase mix: 77 late (III/IV) vs 161 early (I/II) (early-phase heavy).

Top condition: Schizophrenia (14 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

University of Maryland, Baltimore: open-pipeline peers nationwide

Peers matched on 560 registered trials and 18% open enrollment, not the therapeutic-area sidebar.

University of Maryland, Baltimore sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 02004006008001,000 5%10%15%20%25% Total trials Recruiting share University of Maryland, BaltimoreAmgenMerck Sharp & DohmeVirginia Commonwealth UniversityNational Institute of Neurological Disorders and Stroke (NINDS)Abramson Cancer Center at Penn MedicineHenry Ford Health SystemNew York Institute of TechnologyUniversity of California, San Diego
University of Maryland, Baltimore sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

University of Maryland, Baltimore sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 560 trials (± recruiting share)

Sponsors near 18% open enrollment (± trial volume)

What to do with this University of Maryland, Baltimore page

560 registered trials is a research-attention snapshot, not an endorsement of University of Maryland, Baltimore or any single study.

  • 103 of University of Maryland, Baltimore's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Schizophrenia is the condition University of Maryland, Baltimore studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Schizophrenia trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. University of Maryland, Baltimore pipeline card: 560 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.